SCHEMBL1613449

SCHEMBL1613449

Cc1nn2c(=O)cc(-c3ccc(Cl)cc3)[nH]c2c1-c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.48
NPC1 O15118 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
KMT2A Q03164 4/20 0.46
MEN1 O00255 2/20 0.46
RAB9A P51151 1/20 0.46
MAPT P10636 4/20 0.44
ALDH1A1 P00352 3/20 0.41
GAA P10253 3/20 0.41
KDM4E B2RXH2 2/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
LMNA P02545 2/20 0.40
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
ARF6 P62330 2/20 0.39
PDE10A Q9Y233 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13516328 1.00 TP53 (0.48) TP53NPC1NPSR1KMT2AMEN1
SCHEMBL13515966 0.95 MAPT (0.46) TP53NPC1NPSR1KMT2AMEN1
SCHEMBL1614504 0.92 ADORA2A (0.45) TP53NPC1NPSR1KMT2AMEN1
SCHEMBL13516556 0.90 ADORA2A (0.41) TP53NPC1KMT2AMEN1RAB9A
SCHEMBL1614418 0.89 PSD (0.45) TP53NPC1KMT2AMEN1RAB9A
SCHEMBL19084549 0.89 PSD (0.45) TP53NPC1KMT2AMEN1RAB9A
SCHEMBL24221653 0.88 PLAT (0.43) TP53NPC1RAB9AMAPTALDH1A1
SCHEMBL13516682 0.88 CDC7 (0.46) NPC1NPSR1KMT2AMEN1RAB9A
SCHEMBL13516471 0.88 PLAT (0.43) TP53NPC1RAB9AMAPTALDH1A1
SCHEMBL13516124 0.87 GCGR (0.44) NPC1KMT2AMEN1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170216332-A1 SMALL MOLECULE ANTI-SCARRING AGENTS UNIVERSITY OF ROCHESTER (US) 2017-08-03 US claimed
WO-2015195684-A2 SMALL MOLECULE ANTI-SCARRING AGENTS UNIVERSITY OF ROCHESTER (US) 2015-12-23 WO claimed
US-20220023270-A1 ANTIBACTERIAL COMPOUNDS AND USES THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2022-01-27 US disclosed
US-10953012-B2 Heterocyclic compounds for the inhibition of pask BIOENERGENIX LLC (US) 2021-03-23 US disclosed
US-10953012-B2 Heterocyclic compounds for the inhibition of pask BIOENERGENIX LLC (US) 2021-03-23 US disclosed
US-10548911-B2 Small molecule anti-scarring agents UNIVERSITY OF ROCHESTER (US) 2020-02-04 US disclosed
US-10548911-B2 Small molecule anti-scarring agents UNIVERSITY OF ROCHESTER (US) 2020-02-04 US disclosed
US-20170216332-A1 SMALL MOLECULE ANTI-SCARRING AGENTS UNIVERSITY OF ROCHESTER (US) 2017-08-03 US disclosed
US-20170216332-A1 SMALL MOLECULE ANTI-SCARRING AGENTS UNIVERSITY OF ROCHESTER (US) 2017-08-03 US disclosed
WO-2015195684-A2 SMALL MOLECULE ANTI-SCARRING AGENTS UNIVERSITY OF ROCHESTER (US) 2015-12-23 WO disclosed
WO-2015195684-A2 SMALL MOLECULE ANTI-SCARRING AGENTS UNIVERSITY OF ROCHESTER (US) 2015-12-23 WO disclosed
US-8796285-B2 Pyrazolo [1,5-a]-pyrimidones derivatives and pharmaceutical compositions and uses thereof HEBEI MEDICAL UNIVERSITY (CN) 2014-08-05 US disclosed
WO-2012149157-A2 HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK BIOENERGENIX (US) 2012-11-01 WO disclosed
US-20120277224-A1 HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK BIOENERGENIX (US) 2012-11-01 US disclosed
US-20120277224-A1 HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK BIOENERGENIX (US) 2012-11-01 US disclosed
US-20120088775-A1 Pyrazolo-[1,5-a]-Pyrimidones Derivatives and Pharmaceutical Compositions and Uses Thereof PEKING UNIVERSITY (CN) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277224-A1 HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK PASK, PDXK, PANK2 TP53 1469/4885NPC1 3570/4885NPSR1 971/4885
US-20170216332-A1 SMALL MOLECULE ANTI-SCARRING AGENTS COLGALT1, MMP1, FIBP TP53 2310/4885NPC1 4426/4885NPSR1 4044/4885
US-20220023270-A1 ANTIBACTERIAL COMPOUNDS AND USES THEREOF CLPP, SPOUT1, MRPL21 TP53 3376/4885NPC1 1188/4885NPSR1 3921/4885
US-20120088775-A1 Pyrazolo-[1,5-a]-Pyrimidones Derivatives and Pharmaceutical Compositions and Uses Thereof KCNJ2, KCNQ5, KCNJ11 TP53 4179/4885NPC1 1230/4885NPSR1 530/4885
US-10953012-B2 Heterocyclic compounds for the inhibition of pask PASK, PDXK, PANK2 TP53 1469/4885NPC1 3570/4885NPSR1 971/4885
US-10548911-B2 Small molecule anti-scarring agents COLGALT1, MMP1, FIBP TP53 2310/4885NPC1 4426/4885NPSR1 4044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.